https://www.unnaturalproducts.com/about-1 daily 0.75 2026-07-22 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/587a2fb6-59f3-4334-8067-ef1a1b74ce91/campye.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/6e7e859a-00cc-4b01-ae7e-d56e4a955ba2/JoshHead+copy.jpg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/88882f42-51bc-492d-bf5e-707e9fb84a54/simon-bailey.jpg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/4586b961-186c-43d9-9ada-538ac2357279/image+%288%29.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/a692c8dd-b1ff-4111-b99d-008205e32935/image+%2810%29.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/587a2fb6-59f3-4334-8067-ef1a1b74ce91/campye.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/071bbb60-f11f-421e-bc7a-7c37393ffd8f/mert_head.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/c5addace-5c8f-452a-9ef4-3022e5c9ab00/a-kazimi.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/51c7cd86-bdb6-4943-aa58-3e63e11cd404/s-peterson.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7a934ab8-03ae-4423-9c5f-37c3eeb90c31/w-taranto.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/66100849-c636-4cd0-a474-1305c8f6a585/mark%29head.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/14aaf755-d67e-4360-8c45-e88aaaf55416/l-matheakas.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/63676591-aaab-4302-bd5e-1e4acd0d7af7/s-lokey.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/fe59f677-c591-4735-9a2f-e4f3b3f28bf4/t-sawyer.jpeg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f66e6bf2-331d-48fa-ab3c-c645e5ace66b/n-thornberry.jpeg https://www.unnaturalproducts.com/careers daily 0.75 2026-07-21 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/934697f1-68b2-4fd6-b7d0-fade9d8c3edd/UNP_Logo_ICON_250-01.png https://www.unnaturalproducts.com/home daily 1.0 2026-07-22 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/1c47b1db-12cd-4443-b5f9-6416080f1561/nvs_blk.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/05db3c15-39c6-4332-a991-f698887cbd24/argenx-2_edited.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/ba8e4493-d68a-4e57-a2f2-88e401619c72/Bitmap+4.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/5c5cd56e-ffde-48e0-8cf3-2a16d4327858/wing_blk.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7f96a3c3-2f48-444b-a459-91eec18b7f8c/00d1e1_5fbe3fad9a084f8fbfdb80665bfde1a0%7Emv2.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7fd15f9d-b91a-441f-961b-aa11881785e3/Bitmap.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/50111a64-44a8-4982-a7ff-2b027437883e/logo_greyscale_v2.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/0e5d5c82-4d35-4909-a57e-a03dc4fddb86/bridgebio-logo-green.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/18517987-50b1-424e-8ce1-aa54f3d8f184/MerckPaleTeal_edited.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/3be9db57-f2ac-45b6-bd47-7704b30feee3/Bitmap+2.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/d9083714-0b54-493a-8d1d-ff5808a8a2cc/Bitmap+3.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/cb98c35a-1780-4dab-ad54-9e9418918e27/BBV-Square-unp.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/c3bc3470-768b-447f-aa7c-42a987d34c13/Asset+3.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/bb953399-8f48-4878-a722-c71e8cf1763d/00d1e1_f79f3aa58fc24f1b872dd3e9eb68042c%7Emv2.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/22306bc2-81a7-42a4-886c-28cb5294307a/Merck-Global-Health-Innovation-Fund-logo.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/ca40332a-7d93-403d-8e74-87f29d6eda17/Presentation1.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/390da356-4e13-4bf6-9b72-d68a3373a686/platform.jpg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/5c2d2e74-d588-4a1f-90bd-f833a999092f/examplebbio.jpg https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/44bc0d50-92e6-4fa7-92f6-fed239d3cfc4/nvs_color-removebg-preview.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/cba22fc8-68c4-4210-a271-fc9253030c6a/512px-Merck_Logo.svg.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/3d05e87c-9669-4e59-901a-16315a5efa7e/argenx.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/a0dd11ee-f6a4-4173-949c-298ebfdaeda4/bridgebio.png https://www.unnaturalproducts.com/news daily 0.75 2026-07-22 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7b8f6ab8-9677-4a24-b6b4-345c168ed2f2/UNP_Logo_ICON_1200-01.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7b8f6ab8-9677-4a24-b6b4-345c168ed2f2/UNP_Logo_ICON_1200-01.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/44bc0d50-92e6-4fa7-92f6-fed239d3cfc4/nvs_color-removebg-preview.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/3d05e87c-9669-4e59-901a-16315a5efa7e/argenx.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/cba22fc8-68c4-4210-a271-fc9253030c6a/512px-Merck_Logo.svg.png https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/a0dd11ee-f6a4-4173-949c-298ebfdaeda4/bridgebio.png https://www.unnaturalproducts.com/director-senior-director-biology daily 0.75 2026-08-19 https://www.unnaturalproducts.com/about-4 daily 0.75 2026-08-25 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f1034e23-5ba0-4b8b-9ffe-43aae2e34c79/Cameron+Pye+Headshot+Photo+Updated+2026.jpg About Cameron Pye, PhD Co-Founder & CEO UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f1034e23-5ba0-4b8b-9ffe-43aae2e34c79/Cameron+Pye+Headshot+Photo+Updated+2026.jpg About Cameron Pye, PhD UC Santa Cruz PhD in organic chemistry who co-founded UNP during his final year of doctoral work, turning his research on macrocycle cell permeability in the Lokey Lab into a platform to drug the undruggable. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/66100849-c636-4cd0-a474-1305c8f6a585/mark%29head.jpeg About Mark Pruzanski CEO Alentis Therapeutics https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/cd7ec776-e378-4d25-8da2-0f1d7f405f34/Josh+Schwochert+Headshot+Photo+2026.jpg About Joshua Schwochert, PhD Co-Founder & CSO Macrocycle and cyclic peptide expert with a PhD from UC Santa Cruz, whose doctoral collaborations with Pfizer and Eli Lilly on beyond-rule-of-5 pharmacokinetics laid the scientific foundation for UNP's drug discovery platform. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/071bbb60-f11f-421e-bc7a-7c37393ffd8f/mert_head.jpeg About Mert Aktar CEO of Receptive Bio and a life sciences executive with over 20 years of experience bridging science and business, having previously served as SVP and Global Head of Corporate Development & Strategy at Kite Pharma. He also holds board positions with Kyverna Therapeutics, ReAlta Life Sciences, and the UCLA Technology Development Group. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/14aaf755-d67e-4360-8c45-e88aaaf55416/l-matheakas.jpeg About Larry Mattheakis Former SVP Biology Protagonist https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/64ccdb53-c7e6-4587-ad45-77e17418e985/Neera+Ravindran+Headshot+Photo+2026.png About Neera Ravindran, MD, MBA Chief Financial Officer Finance leader with 20+ years of experience across public markets and private biotech. Previously CFO of Kriya Therapeutics, where she led its $270M Series C; VP of Investor Relations at Vir Biotechnology; and Head of Investor Relations, North America, at Roche/Genentech. Dr. Ravindran holds an M.D. from Kasturba Medical College and an M.B.A. from the Indian School of Business. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/c5addace-5c8f-452a-9ef4-3022e5c9ab00/a-kazimi.jpeg About Abbas Kazimi CEO and board member of Nimbus Therapeutics, a computational drug discovery company, where he previously served as Chief Business Officer and helped drive transactions totaling over $7 billion. He holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/63676591-aaab-4302-bd5e-1e4acd0d7af7/s-lokey.jpeg About Scott Lokey UCSC Professor and Macrocycle Field Leader https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/ec47cd61-8c36-4afb-9812-bbf9a39f7490/Simon+Bailey+Headshot+Photo+2026.jpg About Simon Bailey, PhD COO & President of R&D Veteran drug discovery leader with 25+ years of experience across Pfizer, Intercept Pharmaceuticals, and Plexium, and recipient of the ACS Hero of Chemistry award for his role in the discovery of Lorbrena™ https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/51c7cd86-bdb6-4943-aa58-3e63e11cd404/s-peterson.jpeg About Stuart Peterson Founder and Managing Partner of ARTIS Ventures, a San Francisco–based tech-bio venture firm known for early investments in YouTube and Stemcentrx. He has served on numerous life sciences boards, including IDbyDNA and Locus BioSciences. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/fe59f677-c591-4735-9a2f-e4f3b3f28bf4/t-sawyer.jpeg About Tomi Sawyer Peptide Drug Hunter, Ex-Merck https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/5efaaeb4-30db-4083-b219-38f4e3dfc329/Lindsay+Young+Headshot+Photo+2026.jpg About Lindsay Young VP Human Resources Lindsay brings broad experience across the HR landscape—people strategy, compliance, talent acquisition, compensation, and building amazing places to work. Before joining Unnatural Products, Lindsay served as the Head of Human Resources at Tempest Therapeutics, and earlier in her career she held various positions in commercial operations at Cepheid and CV Therapeutics. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7a934ab8-03ae-4423-9c5f-37c3eeb90c31/w-taranto.jpeg About William Taranto Founder and President of the Merck Global Health Innovation Fund, Merck's corporate venture arm, which he launched in 2010 and has grown into an evergreen fund with a broad healthcare portfolio. He spent 18 years at Johnson & Johnson in venture and business development roles before joining Merck. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f66e6bf2-331d-48fa-ab3c-c645e5ace66b/n-thornberry.jpeg About Nancy Thornberry Former CEO Kallyope https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/deb85f25-88b2-47a3-92d3-384e5fd8b9a9/Henry+Johnson+Headshot+2026.jpg About Henry Johnson, PhD VP Medicinal Chemistry and CMC Henry W.B. Johnson, PhD, is a drug discovery leader with 20+ years of experience advancing small molecule therapeutics. He has led multidisciplinary R&D teams and contributed to the advancement of several clinical assets from early discovery through late-stage development. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/48e07151-6230-40d0-aeff-72747cbcb5f3/Nicholas+Shekerdemian.jpeg About Nicholas Shekerdemian Founder and Managing Partner of The Venture Collective (TVC), an early-stage venture firm investing at the intersection of deep tech, biotech, and healthcare. A former Thiel Fellow, he previously co-founded and led the AI recruiting startup Headstart. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/29d4d215-d1c3-44dd-b7b3-5868db67c966/Luc+Dochez.jpeg About Luc Dochez Managing Partner of DROIA Genetic Disease Fund and a veteran European biotech entrepreneur and investor with more than 20 years in the industry, best known as former CEO of Tusk Therapeutics, which he led to its acquisition by Roche. He has co-founded multiple companies, including Pharvaris and Vico Therapeutics, and serves as a biotech investor focused on oncology and genetic disease. https://www.unnaturalproducts.com/scientist-ii-or-senior-scientist-medicinal-chemistry daily 0.75 2026-08-19 https://www.unnaturalproducts.com/about daily 0.75 2026-08-25 https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f1034e23-5ba0-4b8b-9ffe-43aae2e34c79/Cameron+Pye+Headshot+Photo+Updated+2026.jpg About Cameron Pye, Ph.D. Chief Executive Officer and Co-Founder Cameron Pye, Ph.D., is Chief Executive Officer and Co-Founder of Unnatural Products (UNP), setting corporate strategy, leading partnering and capital formation, and guiding the scientific direction of the company's discovery platform. He has built his career on the premise that macrocyclic peptides could combine the precision of biologics with the delivery advantages of small molecules, and he has translated that scientific insight into a growing, partnered drug discovery company. Dr. Pye co-founded UNP in 2017, starting in a garage on the west side of Santa Cruz with co-founder Joshua Schwochert. He has grown the company from a two-person startup into a platform company with multiple validating partnerships, including agreements with Novartis, argenx, Merck, and BridgeBio, and has led its private financings while advancing a pipeline in multiple disease areas. This approach grew out of graduate research he conducted on why some cyclic peptides cross cell membranes and others do not, in R. Scott Lokey's laboratory at the University of California, Santa Cruz, where he also met Dr. Schwochert. Dr. Pye earned his Ph.D. in chemistry from the University of California, Santa Cruz, and his bachelor's degree from Whittier College. He currently serves on the Dean's Council of the University of California, Santa Cruz. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f1034e23-5ba0-4b8b-9ffe-43aae2e34c79/Cameron+Pye+Headshot+Photo+Updated+2026.jpg About Cameron Pye, Ph.D. Cameron Pye, Ph.D., is Chief Executive Officer and Co-Founder of Unnatural Products (UNP), setting corporate strategy, leading partnering and capital formation, and guiding the scientific direction of the company's discovery platform. He has built his career on the premise that macrocyclic peptides could combine the precision of biologics with the delivery advantages of small molecules, and he has translated that scientific insight into a growing, partnered drug discovery company. Dr. Pye co-founded UNP in 2017, starting in a garage on the west side of Santa Cruz with co-founder Joshua Schwochert. He has grown the company from a two-person startup into a platform company with multiple validating partnerships, including agreements with Novartis, argenx, Merck, and BridgeBio, and has led its private financings while advancing a pipeline in multiple disease areas. This approach grew out of graduate research he conducted on why some cyclic peptides cross cell membranes and others do not, in R. Scott Lokey's laboratory at the University of California, Santa Cruz, where he also met Dr. Schwochert. Dr. Pye earned his Ph.D. in chemistry from the University of California, Santa Cruz, and his bachelor's degree from Whittier College. He currently serves on the Dean's Council of the University of California, Santa Cruz. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/66100849-c636-4cd0-a474-1305c8f6a585/mark%29head.jpeg About Mark Pruzanski CEO Alentis Therapeutics https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/cd7ec776-e378-4d25-8da2-0f1d7f405f34/Josh+Schwochert+Headshot+Photo+2026.jpg About Joshua Schwochert, Ph.D. Co-Founder and Chief Scientific Officer Joshua Schwochert, Ph.D., is Chief Scientific Officer and Co-Founder of Unnatural Products (UNP), setting the company's scientific direction and target selection and leading its chemistry and computational chemistry organizations. He is a macrocycle and cyclic peptide expert whose doctoral collaborations with Pfizer and Eli Lilly on beyond-rule-of-5 pharmacokinetics laid the scientific foundation for the company's discovery platform. Dr. Schwochert co-founded UNP in 2017, starting in a garage on the west side of Santa Cruz with co-founder Cameron Pye. His graduate research helped establish the relationship between two-dimensional structure, three-dimensional conformation, and the physicochemical and pharmacokinetic properties of cyclic peptides, conducted in Prof. R. Scott Lokey's laboratory at the University of California, Santa Cruz. Over the company's first seven years, he oversaw construction of the empirical discovery platform and the development of parallel synthesis and experimentation technologies. He spearheaded its earliest collaborations, which became the proving ground for additional validating partnerships now spanning BridgeBio, Merck, argenx, and Novartis. Dr. Schwochert earned his Ph.D. in chemistry and biochemistry from the University of California, Santa Cruz, and holds a bachelor's degree in chemistry and biology from Concordia University Irvine. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/071bbb60-f11f-421e-bc7a-7c37393ffd8f/mert_head.jpeg About Mert Aktar CEO of Receptive Bio and a life sciences executive with over 20 years of experience bridging science and business, having previously served as SVP and Global Head of Corporate Development & Strategy at Kite Pharma. He also holds board positions with Kyverna Therapeutics, ReAlta Life Sciences, and the UCLA Technology Development Group. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/14aaf755-d67e-4360-8c45-e88aaaf55416/l-matheakas.jpeg About Larry Mattheakis Former SVP Biology Protagonist https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/64ccdb53-c7e6-4587-ad45-77e17418e985/Neera+Ravindran+Headshot+Photo+2026.png About Neera Ravindran, M.D., M.B.A. Chief Financial Officer Neera Ravindran, M.D., M.B.A., is Chief Financial Officer of Unnatural Products (UNP), leading financial strategy and operations, and supporting business development and execution of corporate strategy. She has more than 20 years of deep public markets and private company experience, with a demonstrated ability to raise capital. Previously, Dr. Ravindran served as CFO of Kriya Therapeutics, where she led its $270M Series C financing, scaled the finance organization, and built the financial foundation to support the company's growth. She also held the role of VP of Investor Relations for Vir Biotechnology during a period of rapid growth and evolution as the company grew from under $2 billion to $7 billion in market capitalization, including a successful $345 million raise in a public stock offering. Before this, Dr. Ravindran was Head of Investor Relations, North America, at Roche/Genentech and VP of Investor Relations and Strategic Planning at The Medicines Company. Earlier in her career, she served as a biotechnology equity research analyst at Piper Jaffray & Company. Dr. Ravindran earned her medical degree from Kasturba Medical College and an M.B.A. from the Indian School of Business. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/c5addace-5c8f-452a-9ef4-3022e5c9ab00/a-kazimi.jpeg About Abbas Kazimi CEO and board member of Nimbus Therapeutics, a computational drug discovery company, where he previously served as Chief Business Officer and helped drive transactions totaling over $7 billion. He holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/63676591-aaab-4302-bd5e-1e4acd0d7af7/s-lokey.jpeg About Scott Lokey UCSC Professor and Macrocycle Field Leader https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/ec47cd61-8c36-4afb-9812-bbf9a39f7490/Simon+Bailey+Headshot+Photo+2026.jpg About Simon Bailey, Ph.D., M.B.A. Chief Operating Officer and President of Research and Development Simon Bailey, Ph.D., M.B.A., is Chief Operating Officer and President of Research and Development of Unnatural Products (UNP), overseeing company operations and leading the R&D organization's scientific and technical strategy. He brings more than 25 years of drug discovery and early development experience in oncology and metabolic disease, across big pharma and public and private biotech companies. Dr. Bailey joined UNP in 2024 from Plexium, where he was Executive Vice President of Drug Discovery and led the company's science and technology groups in identifying novel molecular glue protein degrader drugs. Prior to that, he was Senior Vice President and Head of Research for Intercept Pharmaceuticals, leading the company's programs in NASH/MASH from inception through Phase 1. Earlier in his career, he was a medicinal chemist at Pfizer, where he led the Diabetes and Oncology Medicinal Chemistry departments. He received the American Chemical Society's Hero of Chemistry award for his leadership role in the discovery of lorlatinib, a macrocyclic inhibitor of mutant ALK kinase for the treatment of non-small cell lung cancer. Dr. Bailey earned his Ph.D. in synthetic organic chemistry from the University of Manchester, where he received the Hibbet Prize, and his M.B.A. from the University of California, San Diego, Rady School of Management. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/51c7cd86-bdb6-4943-aa58-3e63e11cd404/s-peterson.jpeg About Stuart Peterson Founder and Managing Partner of ARTIS Ventures, a San Francisco–based tech-bio venture firm known for early investments in YouTube and Stemcentrx. He has served on numerous life sciences boards, including IDbyDNA and Locus BioSciences. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/fe59f677-c591-4735-9a2f-e4f3b3f28bf4/t-sawyer.jpeg About Tomi Sawyer Peptide Drug Hunter, Ex-Merck https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/5efaaeb4-30db-4083-b219-38f4e3dfc329/Lindsay+Young+Headshot+Photo+2026.jpg About Lindsay Young Vice President, Human Resources Lindsay Young is Vice President of Human Resources of Unnatural Products (UNP), leading people strategy, organizational design, and the HR systems, compliance, and facilities functions that support them. She has spent her career building the people infrastructure that companies need as they mature, working closely with executive teams to build talent, compensation, and governance infrastructure that supports company growth. Ms. Young previously served as Executive Director and Head of Human Resources at Tempest Therapeutics, where she led the human resources function through the company's transition to public company operations, establishing the policies and controls expected under Sarbanes-Oxley 404(a) and partnering with finance on corporate governance and Board Compensation Committee matters. She brought benefits, payroll, and HR systems in-house and designed the recruiting, compensation, and performance frameworks that supported the organization as its clinical programs advanced. Earlier, she advised private equity and life sciences leaders as an independent human resources consultant on workforce planning, organizational structure, and recruitment. She began her career in operations and marketing roles at Cepheid and CV Therapeutics, later acquired by Gilead Sciences. Ms. Young earned her bachelor's degree in American Studies from the University of California, Santa Cruz. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/7a934ab8-03ae-4423-9c5f-37c3eeb90c31/w-taranto.jpeg About William Taranto Founder and President of the Merck Global Health Innovation Fund, Merck's corporate venture arm, which he launched in 2010 and has grown into an evergreen fund with a broad healthcare portfolio. He spent 18 years at Johnson & Johnson in venture and business development roles before joining Merck. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/f66e6bf2-331d-48fa-ab3c-c645e5ace66b/n-thornberry.jpeg About Nancy Thornberry Former CEO Kallyope https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/deb85f25-88b2-47a3-92d3-384e5fd8b9a9/Henry+Johnson+Headshot+2026.jpg About Henry Johnson, Ph.D. Vice President, Medicinal Chemistry and CMC Henry W. B. Johnson, Ph.D., is Vice President of Medicinal Chemistry and CMC of Unnatural Products (UNP), leading discovery chemistry and CMC strategy across the company's internal pipeline and partnerships. He brings more than 20 years of experience in the biopharmaceutical industry, having contributed to programs that have produced two FDA-approved medicines and more than 10 clinical-stage assets. Dr. Johnson previously served as Vice President of CMC and Medicinal Chemistry at Tempest Therapeutics, where he supported a portfolio including oral oncology candidates amezalpat and TPST-1495, both in Phase 2 development. As Executive Director and Head of Chemistry at BridGene Biosciences, he directed medicinal chemistry efforts, including the advancement of the covalent TEAD inhibitor BGC515. Earlier, as a Director at Kezar Life Sciences, he led medicinal chemistry and CMC for zetomipzomib, a subcutaneously administered immunoproteasome inhibitor studied in Phase 2 for autoimmune diseases, as well as for the oncology candidate KZR-261. He began his career at Exelixis, Amgen, and Onyx Pharmaceuticals, where he contributed to first-in-class programs across multiple disease areas, including the development of esaxerenone, a hypertension therapy co-developed with Daiichi Sankyo and approved in Japan. Dr. Johnson earned his Ph.D. in chemistry from the University of Utah and his bachelor's degree in biochemistry from California Polytechnic State University, San Luis Obispo. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/48e07151-6230-40d0-aeff-72747cbcb5f3/Nicholas+Shekerdemian.jpeg About Nicholas Shekerdemian Founder and Managing Partner of The Venture Collective (TVC), an early-stage venture firm investing at the intersection of deep tech, biotech, and healthcare. A former Thiel Fellow, he previously co-founded and led the AI recruiting startup Headstart. https://images.squarespace-cdn.com/content/v1/69935fb4f6e8837ad50cba20/29d4d215-d1c3-44dd-b7b3-5868db67c966/Luc+Dochez.jpeg About Luc Dochez Managing Partner of DROIA Genetic Disease Fund and a veteran European biotech entrepreneur and investor with more than 20 years in the industry, best known as former CEO of Tusk Therapeutics, which he led to its acquisition by Roche. He has co-founded multiple companies, including Pharvaris and Vico Therapeutics, and serves as a biotech investor focused on oncology and genetic disease.